Matthew S. Davids, MD, MMSc

Director, Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute (DFCI)

Dr. Matthew Davids is a Boston native and serves as the Director of Clinical Research in the Division of Lymphoma at Dana-Farber Cancer Institute and as an Associate Professor of Medicine at Harvard Medical School in Boston. In the field of chronic lymphocytic leukemia, he cares for patients, leads innovative clinical trials with targeted agents, and runs a translational research lab focused on identifying new combination approaches and elucidating resistance mechanisms to targeted therapies in this disease.

Poster(s):

• 1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL

• 1109 - Real world treatment patterns, reasons for discontinuation, and survival outcomes among patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) receiving second or later lines of therapy in a contemporary population treated in the United States

• 1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study

• 1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING

• 1164 - Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)

• 1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies

• 1207 - A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia

• 1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group

• 2012 - Matching-Adjusted Indirect Comparison of Pirtobrutinib vs Venetoclax Continuous Monotherapy in Patients with Relapsed/Refractory CLL Previously Treated with a Covalent BTK Inhibitor

• 3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)